Backed by top-tier VCs, stealthy biotech bags AlzeCure Alzheimer’s asset in $2.2B deal

Posted inBiotechnology

QuantumCell has licensed AlzeCure Pharma’s Alzheimer’s disease platform and lead asset for $12 million upfront, bagging a potentially symptom-relieving drug candidate that is on the cusp of phase 2.